MORPHOSYS (MOR) - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth
Alliances with GSK and Celgene in 2013 propelled MorphoSys (MOR) in the limelight. This could well be the inflection point in MorphoSys's evolution into a successful mature biotech company on the strength of its innovative platforms to develop biologics. Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are the future drivers. MOR enter into out-licensing deal with CELG for jointly development of MOR-202 (HuCAL antibody targeting CD38) for a total value of €698.8m. CELG strong presence in hematological malignancy further enhances the value with possible expansion in other leukemia’s....... For more detail, please read our report released on September 12, 2013, titled, “MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth ”.
More Publications
MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth
US$ 140.00
June 2013
5 pages
MorphoSys AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
US$ 350.00
July 2018
121 pages
Newport Partners Income Fund Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
US$ 499.00
September 2026
50 pages
